Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors
(HDACis) have positioned these agents as promising drug candidates in combatting cancer …

In recent years, anti-tumor immunotherapy has shown promising results, and immune-
oncology is now emerging as the fourth major wave in the treatment of tumors after …

HDAC inhibitors (HDACIs) are anticancer agents being developed in preclinical and clinical
settings due to their capacity to modulate gene expression involved in cell growth …

Understanding the contribution of dysregulated gene silencing to epigenomic alterations in
cancer development provides the rationale for the use of epigenetic modulators, such as …

Epigenetic modifications, like histone acetylation, are essential for regulating gene
expression within cells. Cancer cells acquire pathological epigenetic modifications resulting …

HDAC inhibitors, which can inhibit the activity of HDAC enzymes, have been extensively
studied in tumor immunotherapy and have shown potential therapeutic effects in cancer …

Bone marrow transplantation is regarded as the most effective immunotherapy for
hematologic cancer, but it generally faces difficulties in matching. Aberrant expression of …

There is a growing body of evidence to support the use of histone deacetylase inhibitors
(HDACi) in the treatment of diverse conditions from autoimmunity to cancer. In this context …

Histone deacetylase (HDAC) inhibitors are powerful epigenetic regulators that have
enormous therapeutic potential and have pleiotropic effects at the cellular and systemic …

Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their
net impact on the evolving antitumor immune response is highly dependent on the inhibitors …